Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
proinsulin peptide C19-A3
- Development stage
- Unknown
- Lead developer
- Cardiff University
- Modality
- Peptides
- Administration
- Intradermal
01
Overview
Proinsulin peptide C19-A3 (PPI C19-A3) is an investigational, antigen-specific peptide immunotherapy developed by Cardiff University in collaboration with King's College London for the treatment of newly diagnosed type 1 diabetes mellitus. The drug consists of an 18-amino acid synthetic peptide (GSLQPLALEGSLQKRGIV) spanning from position 19 of the C-peptide of proinsulin to position 3 of the A-chain. It is designed to target the HLA-DR4 (HLA-DRB1*0401)-restricted T cell response to proinsulin, aiming to restore immune tolerance and halt the autoimmune destruction of pancreatic beta cells. Administered via intradermal injection, PPI C19-A3 has been evaluated in a Phase 1b clinical trial (MonoPepT1De) where it demonstrated safety, tolerability, and signs of beta-cell preservation. A gold nanoparticle-coupled formulation (C19-A3 GNP) has also been developed to enhance its tolerogenic potential.
- Other names
- proinsulin peptide C19-A3C19-A3 peptideC-19-A3 peptideC 19-A3 peptide
02
Targets
HLA-DR4Proinsulin-specific CD4+ T-cell receptor recognizing HLA-DR4–C19-A3 complexHLA-DRB1*04 (HLA class II histocompatibility antigen, DRB1-4 beta chain)
Beyond the preview
Go deeper on proinsulin peptide C19-A3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on proinsulin peptide C19-A3.